<DOC>
	<DOC>NCT01255696</DOC>
	<brief_summary>A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.</brief_summary>
	<brief_title>Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>History of biopsyproven celiac disease Adherence to a glutenfree diet TG2 antibody negative Signed informed consent Active dermatitis herpetiformis History of IgEmediated reactions to gluten Use of specific medications 6 months prior to entry History of alcohol abuse or illicit drug use Current untreated or GI disease Positive pregnancy test Received any experimental drug within 14 days of randomization Uncontrolled chronic disease or condition Uncontrolled complications of celiac disease Any medical condition which could adversely affect study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Celiac Disease</keyword>
	<keyword>Coeliac Disease</keyword>
	<keyword>Celiac Sprue</keyword>
	<keyword>Keliakia Disease</keyword>
</DOC>